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Perhaps everyone is destined to develop heart failure unless they die from something else 
first. Perhaps heart failure cannot be truly prevented unless the ageing process itself can be 
reversed or stopped. However, procrastination is a realistic and worthwhile objective. Heart 
failure is associated with a high mortality and substantial disability, which may be of even 
greater importance to both patients and society (1). Even if we cannot prevent heart failure, 
delaying its onset could improve the lives of billions of people for many years. Indeed, the 
principal reason for treating hypertension, hyperlipidaemia, diabetes mellitus, obesity, atrial 
fibrillation, myocardial infarction and perhaps chronic renal disease is to delay or prevent the 
development of the two most common cardiovascular reasons for chronic disability, heart 
failure and stroke. Treating risk factors has certainly postponed the average age at which 
heart failure and stroke occur, but age will eventually take its toll (2, 3). Nonetheless, health 
professionals and the population at large should not become despondent and should continue 
their efforts to procrastinate, even if prevention proves impossible. However, the resource 
requirements and economic consequences of procrastination are fundamentally different from 
those of prevention. Only if there is “compression” of morbidity and disability (ie:- fewer 
disability-adjusted life-years – DALYs), will procrastination reduce costs (4). 
There are several complementary strategies, other than euthanasia (5), that might reduce 
DALYs due to heart failure. Increasing health education and awareness in the general 
population will reduce cardiovascular morbidity and consequently delay the onset of heart 
failure, although this strategy might be most effective for relatively affluent and well-
educated people who have already reaped many such benefits. Indeed, the substantial age-gap 
between the most and least affluent people with heart failure is probably a good estimate of 
modifiable risk (3). Of note, the prevalence of heart failure is similar regardless of affluence; 
more affluent people just get heart failure at an older age. Another strategy is to identify and 
target individuals who are at high risk of developing heart failure in the next 5-10-years who 
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might benefit from further intervention beyond the routine management of problems such as 
hypertension and hyperlipidaemia. This requires the development of risk-prediction models. 
These must not only predict individuals at high risk but also a large proportion of those who 
develop heart failure. Identifying an individual-patient risk of 20% risk over 10 years that 
predicts only 10% of all cases might be an interesting academic exercise but will be of little 
help in designing an effective prevention strategy for a population. Alternatively, rather than 
prevent heart failure it might be better to manage it better once it develops, either by 
detecting and treating it before it causes substantial disability or by discovering more 
effective interventions after diagnosis. Ultimately, for a problem such as heart failure, all of 
the above may be required.  
In this issue, Khan et al (6) describe the development of a 10-year model for incident heart 
failure. The study population comprised mainly (78%) white men and women drawn from six 
community-based cohorts of people from the United States of America and one from the 
Netherlands enrolled between 1985 and 2000; a time-frame that may no longer reflect 
contemporary clinical practice. Overall, 21,240 people (mean age ~52 years) were enrolled, 
of whom 2,552 (12%) developed heart failure in the following 10 years. Few people aged 
<60 years at baseline will have developed heart failure. Age was the strongest predictor of 
risk by a long-chalk for all groups except men of African-American origin, which may reflect 
the rather small sub-set (only 933 men in the derivation cohort of whom only 109 developed 
heart failure – about 10 cases per year and only 1,066 in the validation cohort of whom only 
29 developed heart failure – about 3 cases per year) in which the predictive models were also 
weakest. A slightly higher proportion of men compared to women and “white” people rather 
than “black” people developed heart failure but after correction for age, the 10-year incidence 
was somewhat higher in black people. Other important predictors for some patients, grouped 
by sex and race, were not a surprise (7) and included hypertension (especially amongst 
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women), smoking (especially amongst white women) and obesity (especially white men and 
black women). The authors report a 10-year incidence of heart failure in people aged 50 years 
with a high-risk profile exceeding 20% for men and black women and 15% for white women, 
which looks impressive. However, the decile of patients at highest risk, which will mostly 
have included people aged >50 years, had an incidence of heart failure of only 12%. 
Accordingly, the very high-risk group in this report must apply to very, very few people 
indeed, which renders a strategy of targeted intervention based on this model unlikely to have 
much impact on the population-incidence of heart failure.   
However, by far the most serious criticism of this analysis is the criteria for case-
ascertainment which were heterogeneous, often subjective and lacked sensitivity. There is, as 
yet, no generally agreed definition of heart failure, which remains a diagnosis largely based 
on subjective criteria that are difficult to verify and validate in retrospect (3). A patient who is 
grossly overweight might say they are breathlessness climbing stairs and have fat ankles, but 
it is not clear that these problems are due to heart failure. Epidemiological work on heart 
failure is plagued by an obsession for specificity rather than sensitivity. Both specificity and 
sensitivity are important, and one should not always be preferred over the other. Clearly, 
applying a diagnosis of heart failure based on unverifiable subjective criteria is unhelpful but 
so is an obsession with specificity. Requiring overt evidence of clinical congestion before 
heart failure is diagnosed means that most patients are so sick at the point of first diagnosis 
that they need to be hospitalised (3, 8). Many people, who might otherwise fulfil all the 
criteria for heart failure, avoid provoking symptoms by adopting a sedentary life-style. On the 
other hand, amongst patients with cardiovascular disease, a substantial proportion have 
elevated plasma concentrations of natriuretic peptides, associated with an increasing 
prevalence of breathlessness and ankle swelling, high morbidity and a poor prognosis. What 
is this if not heart failure?  
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A Universal Definition of Myocardial Infarction based on troponin biomarkers is in its 4th 
iteration and increasingly accepted for epidemiological studies and clinical practice of acute 
coronary syndromes(9). Perhaps it is time to create a first Universal Definition of Heart 
Failure? The hallmark of a failing heart is congestion leading to a rise in plasma 
concentrations of natriuretic peptides and dilatation of the atria and great veins (10, 11). 
Some might argue that there are many reasons for increases in plasma concentrations of 
natriuretic peptides and atrial dilatation but, with rare exceptions, these are always associated 
with an increase in atrial and venous pressures, in other words congestion, and an adverse 
outcome. Congestion is a cardio-renal syndrome of water (with some salt) retention leading 
to increased secretion of natriuretic peptides, which may be viewed as a physiological attempt 
to control congestion. For some patients, congestion will be driven almost exclusively by 
cardiac dysfunction and for others almost exclusively by renal dysfunction, but most patients 
will sit somewhere on the spectrum between these extremes. When an increase in natriuretic 
peptides is associated with dilatation of the atria or great veins this may be considered 
‘congestive’ heart failure (12). A Universal Definition of Heart Failure based on objective 
and verifiable measurements (biomarkers and imaging) that are deranged early in the course 
disease and dissociated from subjective criteria that such as symptoms and signs that only 
appear late will enable earlier intervention. We now need clinical trials to demonstrate that 
interventions based on the Universal Definition of Heart Failure in patients who have few or 
no symptoms improves outcomes. Such trials are underway(3). 
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